At the same time, although many different factors modulate the clinical response to an immune checkpoint inhibitor, the strong relationship between the tumor mutational burden and the activity of anti-PD-1 therapies across multiple cancers has been highlighted and the association of p53 and PD-L1 also suggested. The gene discussed is CD274; the disease is cancer.